MonoSol Rx Completes Ondansetron Bioequivalence Study
February 22, 2008
Drug delivery company MonoSol Rx has successfully completed a pilot clinical study for its thin film formulation of ondansetron used in the prevention and treatment of nausea and vomiting.
Thin film formulation of ondansetron was studied against GlaxoSmithKline’s Zofran ODT product. Based on the results of the study, MonoSol Rx is moving immediately to pivotal trials to enable drug submissions both in the US and Europe.
Mark Schobel, president and CEO of MonoSol Rx, said: “Our thin film formulation of ondansetron is particularly well suited for the target patient population because individuals who are prescribed the drug often have difficulty swallowing due to extreme nausea caused by chemotherapy, radiotherapy and surgical procedures.”